Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer

Authors not listed

Sumitomo Pharma Co., Ltd. · 2006

Abstract

The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
Anonymous. (2006). Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer. <em>Sumitomo Pharma Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT00286169
Vancouver
Anonymous. Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer. Sumitomo Pharma Co., Ltd.. 2006.
BibTeX
@misc{anon2006Random, title = {Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer}, author = {Anonymous}, journal = {Sumitomo Pharma Co., Ltd.}, year = {2006}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings